Radiation therapy of acquired immunodeficiency syndrome-related Kaposi's sarcoma of the eyelids and conjunctiva. 1992

R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
Department of Ophthalmology, University of California, San Francisco 94143.

We retrospectively studied 42 men with acquired immunodeficiency syndrome-related Kaposi's sarcoma of the conjunctiva or eyelids who were treated with radiation. Forty-nine sites were treated, 35 (71%) of which involved the eyelids, 12 (24%) the conjunctiva, and two (4%) both the eyelids and conjunctiva. Group 1 consisted of 31 sites treated with a single dose of 800 cGy and group 2 consisted of 18 sites treated with a multiple-fraction regimen and total doses between 1500 and 3600 cGy. The response and recurrence rates in the two groups were similar. One patient from group 2 died within 1 month of treatment and was not included in the analysis. The lesions improved in all cases. A complete response was obtained in 10 (32%) of the 31 lesions in group 1, compared with four (22%) of 18 lesions in group 2. A partial response was obtained in 21 (68%) of 31 lesions in group 1, compared with 13 (72%) of 18 lesions in group 2. Expected minor reactions in the treatment field, primarily loss of cilia, were comparable in the two groups. No serious complications were noted. Recurrence occurred in seven (22%) of the 31 sites in group 1 (six patients) and seven (39%) of the 18 sites in group 2 (six patients). The results suggest that a single treatment of 800 cGy is a safe and effective palliative therapy for ophthalmic acquired immunodeficiency syndrome-related Kaposi's sarcoma.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D003230 Conjunctival Neoplasms Tumors or cancer of the CONJUNCTIVA. Conjunctival Neoplasm,Neoplasm, Conjunctival,Neoplasms, Conjunctival
D005142 Eyelid Neoplasms Tumors of cancer of the EYELIDS. Eyelid Neoplasm,Neoplasm, Eyelid,Neoplasms, Eyelid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
May 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
September 1995, Mayo Clinic proceedings,
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
August 1991, The Journal of urology,
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
June 1989, Archives of ophthalmology (Chicago, Ill. : 1960),
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
August 2003, Acta ophthalmologica Scandinavica,
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
February 1985, Journal of the Royal Society of Medicine,
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
January 1984, The New Zealand medical journal,
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
May 1986, The Medical clinics of North America,
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
September 1995, American journal of obstetrics and gynecology,
R Ghabrial, and J M Quivey, and J P Dunn, and D H Char
September 2008, The Journal of laryngology and otology,
Copied contents to your clipboard!